cartouche ECN WORKSHOP
-

Abstracts

Oral communications

1

2019 - Oral communication

Therapeutics-Miscellaneous

The first phase 2a proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrile™ (OLT1177™), in acute gout

T. L. Jansen (1), V. Klück (2), M. Janssen (1), A. Comarniceanu (1), M. Efdé (1), C. L. Scribner (3), R. B. Barrow (3), D. B. Skouras (3), C. A. Dinarello (3,4), L.A.B. Joosten (2)

3

2019 - Oral communication

Therapeutics-Miscellaneous

Extracellular DNA drives tissue necrosis upon cholesterol crystal embolism

C. Shi (1), T. Kim (1), S. Steiger (1), S. R. Mulay (1), B. Klinkhammer (2), P. Boor (2), HJ. Anders (2)

4

2019 - Oral communication

Rare diseases

The chicken and egg situation: on the role of uric acid crystal granulomas in chronic kidney disease

M. Sellmayr (1), Mr. Hernandez Petzsche (1), Q. Ma (1), H. Liapis (2) , B. Lenz (3), A. Brink (3), Ml. Angelotti (4), P. Romagnani (4), Hj. Anders (1), S. Steiger (1)

6

2019 - Oral communication

Mechanisms-Epidemiology

Prevalence of intra-articular mineralization on knee ct: the multicenter osteoarthritis study

T. Neogi, M. Jarraya, J. Lynch, M. Clancy, D. Felson, M. Nevitt, Ce. Lewis, J. Torner, A. Guermazi

7

2019 - Oral communication

OA-Genetics and EUROGOUT-Inflammation

Hyperuricemia impairs b2 integrin-mediated neutrophil migration in acute gouty arthritis during renal failure

Q. Ma1, R. Immler ², M. Pruenster ², M. Honarpisheh ¹, M. Lindenmeyer 1,3, M. Sellmayr ¹, C. Böhland 4, M. Sperandio ², HJ. Anders ¹ & S. Steiger ¹.

Posters

9

2019 - Poster

Therapeutics-Miscellaneous

Serum ros products, no radicals and ascorbate radicals in gout patients are not associated with diastolic dysfunction of the heart and treatment with allopurinol or febuxostat

R. Gancheva (1), A. Koundurdjiev (2), G. Nikolova (3), M. Ivanova (1), T. Kundurzhiev (4), Z. Kolarov (1), V. Gadjeva (3)

10

2019 - Poster

Therapeutics-Miscellaneous

Renoprotective effect of urate lowering therapy in gouty patients with moderate chronic kidney disease

E. Calvo (1), M. Novella (2), F. Aramburu (3), L. Janta (4), A. Prada (2)

12

2019 - Poster

Therapeutics-Miscellaneous

OLT1177™, an oral NLRP3 inflammasome inhibitor, inhibits acute joint inflammation and circulating il-1β during gout flares in humans

V. Klück (1), T. Jansen (2), M. Janssen (2), I. W. Tengesdal (1,4), K. Schraa (1), D. B. Skouras (3), C. Marchetti (4), C. A. Dinarello (1,4) and L. A.B. Joosten 1(,5)

13

2019 - Poster

OA-Genetics and EUROGOUT-Inflammation

Alpha-1-antitrypsin in relation to serum urate and inflammatory markers in patients; comparison between gout, asymptomatic hyperuricaemia and healthy controls.

I. Hotea (1), T. O. Crisan (2), C. Pamfil (1), M. Badii (2), O. Gall (2), L. Peca (2), A. Mirea (2), R. Popp (2), S. Rednic (1,3), L. Ab Joosten (2,4).

14

2019 - Poster

OA-Genetics and EUROGOUT-Inflammation

2,8 dihydroxyadenine nephropathy: critical role of crystal-induced inflammation

Elise Bouderlique (1), Ellie Tang (1, Sophie Vandermeersch (1), Joelle Perez (1), Dominique Bazin (2), Vincent Frochot (3), Ea Hang-Korng (4), Michel Daudon (3), Emmanuel Letavernier (1,3)

15

2019 - Poster

OA-Genetics and EUROGOUT-Inflammation

Polynesian specific gout associated missense variants in LRP2

M. Leask (1), T. Fatima (1), A. Jones (1), M. Cadzow 1, N. Dalbeth (5), L. Stamp (7), J. H. Hindmarsh (6), D. Mount (3), E. Stahl (2), H. Choi (4) and T. Merriman (1)

16

2019 - Poster

OA-Genetics and EUROGOUT-Inflammation

Involvement of SOCS3 regulation in urate-induced proinflammatory effects

M. Badii (1), O. Gaal (1), V. Kluck (2), G. Cabau (1), L. Peca (1), C. G. Andra (1), R. Popp (1), T. Octavia Crișan (1), L. A. B. Joosten (1,2) and the Hint Consortium

17

2019 - Poster

Mechanisms of Calcification

Role of CPPD crystals in chondrocyte differentiation during OA

F. Meyer (1), U. Kornak (2), M. Bollmann (1), C. H. Lohmann (1), J. Bertrand (1)

19

2019 - Poster

OA-Genetics and EUROGOUT-Inflammation

The role of IGF-1R in urate induced inflammation

O. Gaal (1), M. Badii (1), G. Cabau (1), T. O. Crișan 1, M. F. Farcaș (1), I. Hotea (2), C. Pamfil (2), S. Rednic (-2), R. A. Popp (1), L.a.b. Joosten (1,3), Hint Consortium

20

2019 - Poster

Therapeutics-Miscellaneous

Design and preliminary results of a feasibility study on monitoring gout flares with an app

B.P.H. Pouls (1,2), B.J.F. Van Den Bemt (1,2), A.l. Gaffo (3), M. Flendrie (1)

21

2019 - Poster

Mechanisms-Epidemiology

Phenotype of patients with early onset gout

J. Herrou (1), O. Al tabaa (1), E. Gazaix fontaine (1), F. Lioté (1,2), T. Bardin (1,2), P. Richette (1,2), A. Frazier ¹ and h-k. Ea (1,2)

22

2019 - Poster

Mechanisms-Epidemiology

Metabolic syndrome in patients with gout attended in a specialized outpatient unit in spain. Comparison with general population and cardiovascular implications

E. Calvo Aranda, F. M. Sanchez Aranda, L. Cebrian Mendez, M. Angeles Matias De La Mano, E. Garcia Lorenzo, M. T. Navio Marco

26

2019 - Poster

Mechanisms-Epidemiology

The impact of dysfunctional variants of abcg2 on hyperuricemia and gout in pediatric-onset patients

B. Stiburkova 1,3, K. Pavelcova 1,2, M. Pavlikova 1, P. Ješina 3, K. Pavelka 1

29

2019 - Poster

Rare diseases

Medicine crystal mediated pathologies in colonic epithelial and immune cells

T. Kim 1, S. Lautenschlager 2, S. Steiger 1, Hj. Anders 1

31

2019 - Poster

Mechanisms-Epidemiology

Does therapeutic education improve gout management: the experience of lariboisière university hospital paris-france.

O. Al Tabaa ¹, E. Gazaix Fontaine ¹, J. Herrou ¹, F. Lioté 1, 2, T. Bardin 1, 2, P. Richette 1, 2, A. Frazier 1 And H-K. Ea 1, 2

32

2019 - Poster

Mechanisms-Epidemiology

Anecdotal reports of gout flare triggers include a wide range of foods and differ between countries

T. J. Major 1, R. K. Topless 1, T. Neogi 2, C. A. Chen 2, L. K. Stamp 1, N. Dalbeth 4, Y. Zhang 5, H. K Choi 5, T. R. Merriman 1